A maternal vaccine designed to help protect infants from respiratory syncytial virus (RSV), a major cause of severe respiratory infections and pneumonia in young children, has been prequalified by the ...

GSK alleges Pfizer infringed four of its patents in developing a competing RSV vaccine – Copyright GETTY IMAGES NORTH AMERICA/AFP/File SPENCER PLATT GlaxoSmithKline ...

Adults between 18 and 59 who face elevated risk of severe respiratory syncytial virus infection now have a licensed vaccine option. The FDA issued a supplement approval letter for Pfizer’s Abrysvo on ...

As fall approaches, so does the risk of seasonal illness, though infection rates in Massachusetts and across the country ...

The Food and Drug Administration (FDA) has approved Pfizer’s vaccine, Abrysvo, which protects adults 60 and older from the respiratory syncytial virus (RSV), Pfizer announced on Wednesday. The ...

Pfizer Abrysvo received EU approval for use in both older adults and pregnant women to protect infants from respiratory syncytial virus. This product is driving the price of Pfizer Inc. stock (ISIN ...

England’s National Health Service announced on Thursday that three million more older adults in the country will be eligible to receive Pfizer’s (PFE) respiratory syncytial virus (RSV) vaccine, ...

As COVID-19’s disproportionate impact on older people has grabbed many of the headlines during the pandemic, it’s important to remember that millions of babies and young children, particularly in ...

The WHO says multiple-dose vials will make it easier and less expensive to immunize pregnant women in low-income countries.

The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes ...